In a study including 5764 patients undergoing coronary angiography, microvascular dysfunction coexisted with epicardial CAD and was associated with a higher risk of the composite of death, MI, revascularisation, or hospitalisation for HF https://t.co/JZwI7lRmV8 @TheLancet
Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR trial. Early TAVR versus clinical survelliance consistent among all age groups above 65 years @kashishgoelmd@PhilGenereuxMD https://t.co/3SGDxiXhcF
Myth: “Nutrition is simply about avoiding vitamin deficiencies.”
Truth: Vitamins transformed medicine and saved millions from diseases like pellagra, scurvy, and beriberi.
But chronic disease requires us to move beyond nutrient arithmetic.
Food affects metabolism, inflammation, the microbiome, and long-term health.
Real-world studies of GLP-1 discontinuation showed that patients often regain weight at a significantly faster pace than after other weight-loss methods. At the same time, however, novel strategies aimed at countering those effects are showing promise.
The heightened interest in alternatives comes amid reports estimating that 50%-65% of patients prescribed GLP-1s discontinue treatment within the first year, despite the well-documented risk for weight regain. Common contributors to discontinuation include cost, side effects, and insurance coverage barriers.
A recent meta-analysis published in The BMJ highlighted how quickly weight can return after GLP-1 discontinuation. To read more on emerging solutions tap the link: https://t.co/dizIbP5dJE
The reason Ozempic makes you feel sick is also part of why it works. It slows your stomach to a crawl, so food sits there and you feel full for hours. Most people accept the nausea as the price of losing weight.
@novonordisk's next drug, zenagamtide, may break that trade. It hit 24% body weight loss over 36 weeks in people, and the new finding presented this month is what sets it apart: it appears to suppress appetite straight from the brain’s hunger circuits, without slowing the stomach at all.
The catch is that the no-slowed-stomach result is still early, shown in animals, not yet confirmed in humans. If it holds, the queasiness that makes people quit may fade, and the rule that you stop these drugs before surgery may stop applying.
The version of these drugs that skips the gut is the one to watch.
60 year male pathologist
Marathon runner
Mild uneasiness, chest pain since 2 days at peak exercise after 25-30 min.
CAC 1384
Htn well controlled
H/o Sarcoidosis(non cardiac)
Plan?
Workup?
Need for any intervention??
Anticoagulation/antiplatelet strategy?
Plans released for a $16 billion mile-long ship capable of carrying 80,000 people.
The 'Freedom Ship' would be home to about 50,000 people, with space for 10,000 tourists and 20,000 crew members.
"The Freedom Ship is envisioned as a permanently mobile city at sea designed for long-term residence rather than short-term travel," the company says.
The ship would be about 8 times the size of the current largest ship in the world, the Royal Caribbean’s Icon of the Seas.
The plans include a 15,000-seat stadium, schools, colleges, shops, clubs, a water park, a music hall, museums, parks, and more.
The ship, which would run on nuclear, would be too large to dock and would remain in international waters.
Freedom Cruise International says it would go around the world every two to three years.
Insane.
New study of 111,646 women: GLP-1 use was linked to about 30% lower breast cancer incidence.
For scale, tamoxifen (the drug we prescribe to prevent it) runs about 38%, minus the endometrial cancer and clot risk.
Not proof yet, but looks very promising.
Facing excessive ostial stent protrusion? Then consider the Side Flap technique, which offers a controlled and reproducible alternative strategy when true-lumen access is not achievable or fails https://t.co/LLp4fOujqW @ccijournal
Must-peruse case of Ellis type III coronary perforation following abrupt rotablation burr exit, managed with prolonged balloon inflation, ping-pong technique, and anticoagulation reversal https://t.co/jAHDAr99ip @ccijournal
Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations @ASCO#ASCO26@OncoAlert
My Toolkit 🧰⚙️🪛: Self-made steerable catheter to cross the aortic valve in severe aortic stenosis
🔗https://t.co/ZFpZV7gDb6
In this article, @Obisht, Won-Keun Kim and Robert R. Flieger describe a self-made steerable catheter system using a 6F EBU guide and the stiff back end of a 0.035″ wire, combined with a hydrophilic straight-end crossing wire, to facilitate crossing of severely stenotic or calcified native or prosthetic aortic valves during TAVI.
The technique is particularly useful in horizontal aortas, bicuspid valves, and massively calcified tricuspid or bioprosthetic valves, where the conventional technique repeatedly fails.
Reviewed by Moritz Seiffert
#interventionalcardiology #CardioEd #cardioX
In a new blog post, Dr. Michelle Kittleson writes that clinical decisions should be driven by the patient’s medical needs, not by physician concerns about their status, expectations, or perceptions.
Read “Very Important Patients”: https://t.co/7hsjVnY53s
I don’t normally retweet oncology but this is tremendous news
I have had many friends and patients die of pancreatic cancer with no effective therapy
Whilst this delays rather than cures, it is clear progress
I've never been at a medical conference where the results have been greeted with a standing ovation
Tremendous breakthrough in pancreatic cancer treatment
Through science
Hard work, rigorous research, clinical trials.
Science
Not the quack pseudoscience of social media
New JACC study | Lp(a) × CAC — a powerful duo for ASCVD risk
With Lp(a)-lowering therapies coming — this data helps us target who benefits most
Don’t treat Lp(a) in isolation.
CAC = 0 + high Lp(a)? Reassure, monitor.
CAC ≥300 + high Lp(a)? 🚨 Aggressive prevention NOW.